Department of BioNano Technology, Gachon BioNano Research Institute, Gachon University, Seongnam, Republic of Korea.
Science Department, International Vaccine Institute, Seoul, Republic of Korea.
Vaccine. 2019 Sep 20;37(40):5954-5961. doi: 10.1016/j.vaccine.2019.08.036. Epub 2019 Aug 26.
L-HBsAg is a third-generation hepatitis vaccine capable of inducing antibodies in non-responders and thus providing potentially therapeutic treatment. In this study, L-HBsAg was administered using microneedles (MN) without an adjuvant to induce intradermal (ID) immunization, and the efficacy of ID immunization was compared with that of intramuscular (IM) immunization that uses a conventional formulation with an adjuvant of aluminum hydroxide (L-HBsAg-AL-IM). The L-HBsAg was dip-coated onto 800-μm-long microneedles made of polylactic acid (PLA). Delivery efficiency and administration time were determined through in vitro experiments using porcine skin. The denaturation of the formulation against sterilization by gamma rays was observed. A storage test and a freeze-thaw cycle test of the microneedles with trehalose as a stabilizer (L-HBsAg-MN-Tre) were observed. An antibody titer of L-HBsAg-MN-Tre was compared with that of the conventional IM immunization of the L-HBsAg solution with aluminum hydroxide (L-HBsAg-AL-IM). The formulation containing L-HBsAg was located on the upper third of the microneedle tips. The formulation on the MN was dissolved and delivered within 30 min of insertion into porcine skin in vitro. Trehalose was selected as a stabilizer, and the stabilizing effect increased with the increase of trehalose content in the solidified formulation. L-HBsAg-MN with 15% of trehalose was stable for 7 days at 40 °C and showed increased stability compared to the conventional liquid formulations. L-HBsAg-MN-Tre showed improved stability during the freeze-thaw cycle. The antibody titer of L-HBsAg-MN-Tre at 28 days was higher than that of L-HBsAg-AL-IM. ID administration of L-HBsAg-MN-Tre showed better efficacy and improved thermal and freeze thaw stability compared to L-HBsAg-AL-IM. Therefore, L-HBsAg-MN-Tre administration showed the possibility of ID delivery of L-HBsAg without the use of an adjuvant for the efficacy, convenience, and safety of pediatric vaccination.
L-HBsAg 是一种第三代乙肝疫苗,能够诱导无应答者产生抗体,从而提供潜在的治疗效果。在这项研究中,使用微针(MN)给药,无需佐剂,诱导皮内(ID)免疫,将 ID 免疫的效果与使用铝佐剂的常规制剂(L-HBsAg-AL-IM)的肌肉内(IM)免疫进行了比较。将 L-HBsAg 浸涂到由聚乳酸(PLA)制成的 800μm 长的微针上。通过使用猪皮的体外实验来确定递送效率和给药时间。观察了制剂对伽马射线灭菌的变性情况。观察了添加海藻糖作为稳定剂的微针(L-HBsAg-MN-Tre)的储存试验和冻融循环试验。将 L-HBsAg-MN-Tre 的抗体滴度与含铝佐剂的 L-HBsAg 溶液的常规 IM 免疫(L-HBsAg-AL-IM)进行了比较。含 L-HBsAg 的制剂位于微针尖端的上三分之一。在体外将 MN 插入猪皮内 30min 内,制剂溶解并递送到微针上。选择海藻糖作为稳定剂,随着固化制剂中海藻糖含量的增加,稳定效果增强。含有 15%海藻糖的 L-HBsAg-MN 在 40°C 下稳定 7 天,与常规液体制剂相比,稳定性增加。L-HBsAg-MN-Tre 在冻融循环中表现出更好的稳定性。L-HBsAg-MN-Tre 在 28 天时的抗体滴度高于 L-HBsAg-AL-IM。与 L-HBsAg-AL-IM 相比,L-HBsAg-MN-Tre 的 ID 给药显示出更好的疗效以及改善的热稳定性和冻融稳定性。因此,与 L-HBsAg-AL-IM 相比,L-HBsAg-MN-Tre 给药显示了在不使用佐剂的情况下进行 ID 递送 L-HBsAg 的可能性,为儿科疫苗接种提供了疗效、便利性和安全性。